Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Gorovits

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
The AAPS Journal|November 8, 2020
Current Considerations for Immunoglobulin Isotype Characterization of Antibody Response against BiotherapeuticsBoris Gorovits
The AAPS Journal|March 4, 2009
Antidrug antibody assay validation: industry survey resultsBoris Gorovits
Bioanalysis|September 7, 2019
Perspectives on the draft ICH-M10 guidance: an interview with Boris GorovitsBoris Gorovits
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 10, 2019
Immunogenicity of Chimeric Antigen Receptor T-Cell TherapeuticsBoris Gorovits, Eugen Koren
Cancer Immunology, Immunotherapy : CII|December 11, 2012
Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptakeBoris Gorovits, Corinna Krinos-Fiorotti
The AAPS Journal|December 17, 2009
Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serumLi Xue, Rasheeda Johnson, Boris Gorovits
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 24, 2019
Current Considerations on Characterization of Immune Response to Multi-Domain BiotherapeuticsBoris Gorovits, Kun Peng, Arno Kromminga
Bioanalysis|December 18, 2013
PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stabilityAzher Hussain, Boris Gorovits, Mauricio Leal, et al.
Bioanalysis|May 17, 2014
Protein-based matrix interferences in ligand-binding assaysBoris Gorovits, Jim McNally, Corinna Fiorotti, et al.
Bioanalysis|July 31, 2015
Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assaysSeema Kumar, Lindsay E King, Tracey H Clark, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
The AAPS Journal|November 8, 2020
Current Considerations for Immunoglobulin Isotype Characterization of Antibody Response against BiotherapeuticsBoris Gorovits
The AAPS Journal|March 4, 2009
Antidrug antibody assay validation: industry survey resultsBoris Gorovits
Bioanalysis|September 7, 2019
Perspectives on the draft ICH-M10 guidance: an interview with Boris GorovitsBoris Gorovits
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 10, 2019
Immunogenicity of Chimeric Antigen Receptor T-Cell TherapeuticsBoris Gorovits, Eugen Koren
Cancer Immunology, Immunotherapy : CII|December 11, 2012
Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptakeBoris Gorovits, Corinna Krinos-Fiorotti
The AAPS Journal|December 17, 2009
Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serumLi Xue, Rasheeda Johnson, Boris Gorovits
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 24, 2019
Current Considerations on Characterization of Immune Response to Multi-Domain BiotherapeuticsBoris Gorovits, Kun Peng, Arno Kromminga
Bioanalysis|December 18, 2013
PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stabilityAzher Hussain, Boris Gorovits, Mauricio Leal, et al.
Bioanalysis|May 17, 2014
Protein-based matrix interferences in ligand-binding assaysBoris Gorovits, Jim McNally, Corinna Fiorotti, et al.
Bioanalysis|July 31, 2015
Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assaysSeema Kumar, Lindsay E King, Tracey H Clark, et al.
Pageof 8